Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings? [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
The Zacks Consensus Estimate for the company's first-quarter revenues is pegged at $9.23 billion, while the same for earnings is pinned at 77 cents per share, both indicating significant increases from the year-ago quarter. Revenue growth in the first quarter of 2024 is expected to have been driven by strong demand for Novo Nordisk's diabetes and obesity care medicines, especially semaglutide. Notably, semaglutide, a GLP-1 agonist, is approved as an Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes (T2D) and as a Wegovy injection for weight management. Novo Nordisk's revenues under the Rare Disease segment are likely to have declined in the to-be-reported quarter, mainly due to low sales of its hemophilia A products. However, investors are advised not to make investment decisions based on the results of a single quarter. Novo Nordisk, with a market cap of more than $550 billion, has one of the broadest diabetes portfolios in the industry. In the past five yea
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Roche says weight loss drug shows promising results in early trial [CNBC]CNBC
- Roche obesity therapy leads to ~19% weight loss in Phase 1 trial [Seeking Alpha]Seeking Alpha
- Denmark Raises Growth Forecast as Novo Nordisk Expands Output [BNN Bloomberg (Canada)]BNN Bloomberg
- Ozempic maker Novo Nordisk says it will study drug's effects on alcohol consumption but isn't focused on addiction [Yahoo! Finance]Yahoo! Finance
- Ozempic maker Novo Nordisk says it will study drug's effects on alcohol consumption but isn't focused on addiction [CNN]CNN
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/15/24 - Form 6-K
- 5/13/24 - Form 6-K
- 5/13/24 - Form 6-K
- NVO's page on the SEC website